Stock Monitor: China Pharma Holdings Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Eli Lilly and Co. (NYSE: LLY) ("Eli Lilly"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=LLY as the Company's latest news hit the wire. On April 04, 2018, the Company, which is a global healthcare leader, shared positive top-line results from its Phase-3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the second-line treatment of people suffering from hepatocellular carcinoma (HCC). The trial met its primary endpoint of overall survival (OS), as well as the secondary endpoint of progression-free survival (PFS). Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for China Pharma Holdings, Inc. (NYSE American: CPHI), which also belongs to the Healthcare sector as the Company Eli Lilly. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=CPHI
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Eli Lilly most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=LLY
HCC and its Poor Prognosis
HCC, or liver cancer, is the sixth most common cancer worldwide and the second-leading cause of cancer-related death. Every year, around 780,000 new cases of liver cancer are diagnosed worldwide, of which, over 740,000 die of the disease. The incidence of HCC is expected to rise further due to under-diagnosis of chronic liver disease; increasing prevalence of diabetes, obesity, and fatty liver disease; and lack of access to viral hepatitis disease therapy, and the persistent risk of cancer even after viral hepatitis cure.
The prognosis for advanced HCC patients is very poor. Most of HCC patients have limited approved systemic treatments and therapy options as the tumor mostly grow to the extent that resection is not feasible. Nearly half of all advanced HCC patients have high alpha-fetoprotein (AFP-High), defined as an AFP of >=400 ng/mL. This group has the worse prognosis relative to the general HCC patient population. In fact, once patients who are AFP-High enter the second-line treatment setting, the expected survival is three to five months if untreated.
There have been some recent advances, but there still is a very high unmet need for treating HCC patients. Therefore, Eli Lilly is working towards finding suitable treatment options for HCC patients.
About REACH-2 Study
REACH-2 is a global, randomized, double-blind, placebo-controlled Phase-3 study of CYRAMZA® and best supportive care (BSC) compared to placebo and BSC in HCC patients who were intolerant to, or that had disease progression while on, or following treatment with, sorafenib and had high AFP. It must be noted that REACH-2 is the first positive Phase-3 HCC trial in a biomarker-selected patient population.
The trial was initiated in 2015 and enrolled 292 patients across 20 countries in North America, Asia, Europe, and Latin America. The primary endpoint of the REACH-2 trial is overall survival, while key secondary endpoints include progression-free survival, objective response rate, quality of life, and safety.
CRYAMZA® Known to Provide Survival Benefit in Several Tumors
CYRAMZA® is an anti-angiogenic therapy. It is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that exclusively binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. So far, CYRAMZA® has exhibited survival benefit in four aggressive, difficult-to-treat tumor types in Phase-3 studies, including as a single agent in both gastric cancer and HCC.
Phase-3 Results Consistent With Previous Trials
The positive top-line data from the REACH-2 study affirms the hypothesis set by the REACH trial results. The hypothesis was that is a pre-specified subgroup of advanced HCC patients who were AFP-High derived a survival benefit from treatment with CYRAMZA® following first-line treatment with sorafenib.
Moreover, CYRAMZA®'s safety profile reported in the REACH-2 study was in-line with that observed for single-agent CYRAMZA®. The only Grade >=3 adverse events noted at the rate of 5% or greater in the CYRAMZA® arm was hypertension and hyponatremia (low sodium). Eli Lilly intends to submit these efficacy and safety results for presentation at a future medical meeting.
The results from the REACH-2 trial also substantiated Eli Lilly's efforts and commitment towards providing treatment options for people living with HCC and gastrointestinal cancers. In addition to the Phase-3 REACH and REACH-2 trials, Eli Lilly is evaluating CYRAMZA® with an immuno-oncology agent in HCC in a Phase-1b study cohort and is also conducting several studies of CYRAMZA® in other gastrointestinal cancers, including gastric, colorectal, and biliary tract. The Company intends to initiate regulatory submissions in mid-2018.
Stock Performance Snapshot
April 05, 2018 - At Thursday's closing bell, Eli Lilly's stock slightly rose 0.03%, ending the trading session at $78.62.
Volume traded for the day: 2.17 million shares.
Stock performance in the last month - up 1.85%
After yesterday's close, Eli Lilly's market cap was at $85.74 billion.
Price to Earnings (P/E) ratio was at 48.50.
The stock has a dividend yield of 2.86%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers-Major industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
